Skip to playerSkip to main content
Moderna shares surged 12.2% as investors positioned ahead of upcoming health conferences and potential pipeline updates. The stock reached an intraday high of $176.86 before easing to just above $174. Attention is also turning to the company’s personalized cancer vaccine, intismeran autogene, which will feature at the European Society for Medical Oncology’s annual meeting.

For informational and educational purposes only. Not financial advice.

#Moderna #MRNA #Biotech #StockMarket #Healthcare

Category

🗞
News
Transcript
00:00Moderna jumped 12.20% today, ahead of pipeline updates.
00:05Moderna gained 12.20% as investors positioned ahead of upcoming pipeline presentations.
00:13Yahoo! reported that the stock reached a new three-year high before pairing part of its intraday gain,
00:20with two health conferences approaching.
00:22A separate Yahoo! report said Moderna's personalized cancer vaccine,
00:27in Tismarin autogene, was set to feature at the European Society for Medical Oncology's annual meeting.
00:35That made Moderna a company-specific story, rather than simply a reflection of the health care sector,
00:41which rose only 0.34%.
00:45The full recap compares this move with the rest of health care.
00:49Tap the related video.
Comments
After-the-fact Expert
Creator
Do you see Moderna’s pipeline as a lasting growth driver, or is the market getting ahead of the upcoming updates? Share what you’ll be watching most closely.

Recommended